Efficacy and safety of Xa factor antagonists in patients with nonvalvular atrial fibrillation

Factor Xa antagonists are used increasingly frequently for prevention and treatment of venous thromboembolic events stroke systemic emboli in patients with non-valvular atrial fibrillation. Individual characteristics patient, a need prolonged or life-long treatment, concomitant diseases, the use other drugs interacting anticoagulants increase risk side effects anticoagulation. We analyzed current data on efficacy safety factor antagonists, as well features their event adverse reactions, particularly bleedings. The possibilities monitoring these were evaluated.